PDCD1 and hepatocellular carcinoma: One retrospective study focused on HCC patients treated with anti-PD-1 antibodies found that median OS was 5 months in patients with a BMI of less than 25, while it was 17.5 months in patients with a BMI of 25 or greater (Log-rank P=0.034) (119).